We are live on ! Find out more
PLX icon

Protalix BioTherapeutics
PLX

28 hedge funds and large institutions have $19.8M invested in Protalix BioTherapeutics in 2020 Q2 according to their latest regulatory filings, with 14 funds opening new positions, 6 increasing their positions, 2 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

9,467% more call options, than puts

Call options by funds: $1.15M | Put options by funds: $12K

200% more repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 2

180% more first-time investments, than exits

New positions opened: 14 | Existing positions closed: 5

47% more funds holding

Funds holding: 19 → 28 (+9)

41% more capital invested

Capital invested by funds: $14.1M → $19.8M (+$5.71M)

24.21% less ownership

Funds ownership: 40.43% → 16.22% (-24%)

Holders
28
Holders Change
+9
Holders Change %
+47.37%
% of All Funds
0.57%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
14
Increased
6
Reduced
2
Closed
5
Calls
$1.15M
Puts
$12K
Net Calls
+$1.14M
Net Calls Change
+$1.02M

Top Buyers

Rank Fund Capital Flow
1
UOC
UBS O'Connor
Illinois
+$2.3M
2
PF
Phoenix Financial
Israel
+$644K
3
Bank of Montreal
Bank of Montreal
Ontario, Canada
+$594K
4
KCM
Kennedy Capital Management
Missouri
+$347K
5
EMG
ETF Managers Group
New Jersey
+$321K

Top Sellers

Rank Fund Capital Flow
1
HCM
Highbridge Capital Management
New York
-$8.25M
2
SG Americas Securities
SG Americas Securities
New York
-$53K
3
Group One Trading
Group One Trading
Illinois
-$20.4K
4
Victory Capital Management
Victory Capital Management
Texas
-$12K
5
CA
Clearstead Advisors
Ohio
-$1K
Name Holding Trade Value Shares
Change 		Change in
Stake
HCM
1
Highbridge Capital Management
New York
$9.15M -$8.25M -2,414,487 -50%
UOC
2
UBS O'Connor
Illinois
$2.55M +$2.3M +672,035 New
Renaissance Technologies
3
Renaissance Technologies
New York
$2.01M +$181K +53,000 +11%
PVH
4
Psagot Value Holdings
Israel
$1.73M +$218K +63,900 +16%
PF
5
Phoenix Financial
Israel
$681K +$644K +188,336 New
BCM
6
Bridgeway Capital Management
Texas
$661K +$290K +84,799 +95%
Bank of Montreal
7
Bank of Montreal
Ontario, Canada
$615K +$594K +173,704 New
Jane Street
8
Jane Street
New York
$542K +$320K +93,469 +186%
KCM
9
Kennedy Capital Management
Missouri
$384K +$347K +101,387 New
EMG
10
ETF Managers Group
New Jersey
$367K +$321K +93,853 New
California Public Employees Retirement System
11
California Public Employees Retirement System
California
$253K – – –
Walleye Capital
12
Walleye Capital
New York
$222K +$200K +58,609 New
MWPCG
13
Measured Wealth Private Client Group
New Hampshire
$144K – – –
Walleye Trading
14
Walleye Trading
New York
$140K +$126K +36,979 New
Arrowstreet Capital
15
Arrowstreet Capital
Massachusetts
$131K +$118K +34,653 New
Citadel Advisors
16
Citadel Advisors
Florida
$92K +$82.2K +24,047 New
CS
17
Credit Suisse
Switzerland
$38K +$34.2K +10,000 New
VanEck Associates
18
VanEck Associates
New York
$34K +$30.4K +8,906 New
BlackRock
19
BlackRock
New York
$24K +$21.5K +6,284 New
Federated Hermes
20
Federated Hermes
Pennsylvania
$22K – – –
UBS Group
21
UBS Group
Switzerland
$14K +$11.9K +3,474 +1,941%
Simplex Trading
22
Simplex Trading
Illinois
$8K +$7.51K +2,197 New
FDCDDQ
23
Federation des caisses Desjardins du Quebec
Quebec, Canada
$4.17K – – –
Royal Bank of Canada
24
Royal Bank of Canada
Ontario, Canada
$2K -$174 -51 -8%
SPIA
25
Steward Partners Investment Advisory
New York
$1K – – –
1
2

PLX Hedge Fund Activity: Q2 2020 in Review

28 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in Protalix BioTherapeutics (PLX) for Q2 2020, worth a combined $19.8M — up 41% from $14.1M a quarter earlier.

Buyers outnumbered sellers: 14 funds opened new PLX positions and 5 closed out — a net gain of 9 holders — while 6 added to existing stakes and 2 trimmed.

The largest buyer was UBS O'Connor, opening a new position worth an estimated $2.3M. The largest seller was Highbridge Capital Management, cutting an estimated $8.25M.

  • 28 institutional investors held Protalix BioTherapeutics (PLX) as of Q2 2020, up from 19 in Q1 2020.
  • Funds reported $19.8M of Protalix BioTherapeutics stock for Q2 2020, up 41% quarter-over-quarter.
  • 14 funds opened new Protalix BioTherapeutics positions in Q2 2020 and 5 closed out, a net change of +9 holders.
  • The largest Protalix BioTherapeutics buyer in Q2 2020 was UBS O'Connor, an estimated $2.3M added.
  • The largest Protalix BioTherapeutics seller in Q2 2020 was Highbridge Capital Management, an estimated $8.25M sold.

Based on aggregated 13F filings for Q2 2020.